Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging

(2019) Shengnan Liu et al.   CANCER LETTERS

Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation

(2019) Jinchul Kim et al.   CANCER CELL

Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression

(2019) Jianliang Xu et al.   Cell Communication and Signaling

BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics

(2019) Mariana Villalobos-Ortiz et al.   CELL DEATH AND DIFFERENTIATION

Exploiting Mitochondrial Vulnerabilities to Trigger Apoptosis Selectively in Cancer Cells

(2019) Christopher Nguyen et al.   Cancers

Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?

(2019) Amit Mahipal et al.   Cancers

Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers

(2019) Flavia Fondevila et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

A global view of hepatocellular carcinoma: trends, risk, prevention and management

(2019) Ju Dong Yang et al.   Nature Reviews Gastroenterology & Hepatology

Distinct molecular etiologies of male and female hepatocellular carcinoma

(2019) Heini M. Natri et al.   BMC CANCER

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges

(2019) Zuzana Macek Jilkova et al.   Cancers

Recreating Tumour Complexity in a Dish: Organoid Models to Study Liver Cancer Cells and their Extracellular Environment

(2019) van Tienderen et al.   Cancers

Molecular insight of regorafenib treatment for colorectal cancer

(2019) Hiroyuki Arai et al.   CANCER TREATMENT REVIEWS

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

(2019) Sajid Khan et al.   NATURE MEDICINE

BCL-x L -selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis

(2018) Sara Fatima Faqar-Uz-Zaman et al.   CANCER LETTERS

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma

(2018) Anna Tutusaus et al.   Oncotarget

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

(2018) Patricia Gomez-Bougie et al.   BLOOD

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines

(2018) Delphine Merino et al.   CANCER CELL

Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2−/− ) mice

(2017) Anja Moncsek et al.   HEPATOLOGY

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

A pathology atlas of the human cancer transcriptome

(2017) Mathias Uhlen et al.   SCIENCE

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma

(2017) Maria Kissel et al.   Oncotarget

Combenefit: an interactive platform for the analysis and visualization of drug combinations

(2016) Giovanni Y. Di Veroli et al.   BIOINFORMATICS

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells

(2016) Michael Butterworth et al.   BRITISH JOURNAL OF CANCER

Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma

(2016) Jordi Bruix et al.   GASTROENTEROLOGY

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

(2016) E. A. Punnoose et al.   MOLECULAR CANCER THERAPEUTICS

Mitochondria—Judges and Executioners of Cell Death Sentences

(2016) Patrick D. Bhola et al.   MOLECULAR CELL

FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation

(2016) J Tong et al.   ONCOGENE

Cysteine cathepsins control hepatic NF-κB-dependent inflammation via sirtuin-1 regulation

(2016) Álvaro de Mingo et al.   Cell Death & Disease

Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma

(2016) Milica Stefanovic et al.   Oncotarget

BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics

(2015) C Touzeau et al.   LEUKEMIA

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

Angiogenin Secretion From Hepatoma Cells Activates Hepatic Stellate Cells To Amplify A Self-Sustained Cycle Promoting Liver Cancer

(2015) Cristina Bárcena et al.   Scientific Reports

HCC therapies—lessons learned

(2014) Marcus-Alexander Wörns et al.   Nature Reviews Gastroenterology & Hepatology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

NAFLD, NASH and liver cancer

(2013) Gregory A. Michelotti et al.   Nature Reviews Gastroenterology & Hepatology

Development of a novel, physiologically relevant cytotoxicity model: Application to the study of chemotherapeutic damage to mesenchymal stromal cells

(2012) Jennifer E. May et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737

(2011) S. Al-harbi et al.   BLOOD

Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli

(2011) Joan Fernando et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant hep G2 cells through a mitochondria-dependent oxidative stress mechanism

(2010) Jeng-Fong Chiou et al.   CANCER BIOLOGY & THERAPY

ATG12 Conjugation to ATG3 Regulates Mitochondrial Homeostasis and Cell Death

(2010) Lilliana Radoshevich et al.   CELL

The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib

(2010) Hayato Hikita et al.   HEPATOLOGY

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage

(2010) Victoria Tovar et al.   JOURNAL OF HEPATOLOGY

BAD, a Proapoptotic Member of the BCL2 Family, Is a Potential Therapeutic Target in Hepatocellular Carcinoma

(2010) A. Galmiche et al.   MOLECULAR CANCER RESEARCH

Mitochondria and cell death: outer membrane permeabilization and beyond

(2010) Stephen W. G. Tait et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE